StockNews.com Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX)

Investment analysts at StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the stock.

Separately, Maxim Group lowered Moleculin Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th.

Moleculin Biotech Trading Down 2.3 %

Shares of NASDAQ:MBRX opened at $1.26 on Tuesday. The business’s 50 day simple moving average is $1.56 and its two-hundred day simple moving average is $2.18. Moleculin Biotech has a 52-week low of $0.40 and a 52-week high of $10.35.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.